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Abstract 
Genetic alterations initiate tumors and enable the evolution of drug resistance. The pro-cancer 
view of mutations is however incomplete, and several studies show that mutational load can 
reduce tumor fitness. Given its negative effect, genetic load should make tumors more sensitive 
to anticancer drugs. Here, we test this hypothesis across all major types of cancer from the 
Cancer Cell Line Encyclopedia, that provides genetic and expression data of 496 cell lines 
together with their response to 24 common anticancer drugs. We found that the efficacy of 9 out 
of 24 drugs showed significant association with genetic load in a pan-cancer analysis. The 
associations for some tissue-drug combinations were remarkably strong with genetic load 
explaining up to 83% of the variance in the drug response. Overall, the role of genetic load 
depended on both the drug and the tissue type with 10 tissues being particularly vulnerable to 
genetic load. We also identified changes in gene expression associated with increased genetic 
load, which included cell-cycle checkpoints, DNA damage and apoptosis. Our results show that 
genetic load is an important component of tumor fitness and can predict drug sensitivity. Beyond 
being a biomarker, genetic load might be a new, unexplored vulnerability of cancer. 
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Introduction 
Cancer is triggered by the accumulation of driver alterations1–7 and mutations conferring 
resistance to therapy mark the final stages of the disease. Genetic instability accelerates the 
appearance of adaptive mutations and is often viewed as beneficial to cancer. This view is further 
supported by the high prevalence of genomic instability among cancers earning it the status of a 
cancer hallmark8,9. 
 
Besides the few alterations benefiting the tumor, genetic instability produces thousands of other 
changes termed passengers because of their minor role in tumor progression. Traditionally, 
passengers have been considered as noise in cancer genomics because they obscure causative 
mutations that can be used as biomarkers or targets for drug design. However, several recent 
studies challenge this common assumption and suggest that passengers reduce tumor growth10–18. 
Each passenger could be weak and cause a relatively small reduction in fitness due to protein 
misfolding and aggregation, dysregulation of gene expression, or the production of neo-antigens 
for the immune system. The cumulative load of numerous weakly deleterious passengers could 
however result in a substantial fitness cost to the tumor. 
 
Damaging mutations are known to play a major role in evolution19–24, including the intra-host 
evolution of pathogens8,25–27. For cancer tumors, Beckman and Loeb highlighted the potential 
costs of genetic load more than a decade ago16. However, the idea of deleterious passengers has 
not received a lot of attention until the publication of two theoretical papers10,11 that (i) 
demonstrated the plausibility of this hypothesis in the simulations of intra tumor evolution and 
(ii) identified a large number of protein coding changes predicted to reduce tumor fitness. 
Follow-up experiments in mice confirmed that passengers could severely reduce growth rates 
and metastatic ability of cancer cells12. Several clinical studies lend further support to the 
hypothesis of damaging passengers. Patients with highly mutated breast and ovarian cancers 
have been found to survive longer28,29, and clinical trials of immunotherapies in melanoma 
showed efficacy only against cancers with a large number of mutations15. Taken together, these 
results suggest that genetic load reduces many components of tumor fitness30 such as exponential 
growth rate, survival immune attach, and ability to metastasize. It is then natural to expect that a 
high load of passenger mutations should make tumors more susceptible to therapy.     
 
Here, we test this hypothesis and investigate the relationship between genetic load and drug 
response across many types of cancer and anticancer drugs. This analysis has been made possible 
by a large-scale effort that characterized drug response in a genetically and phenotypically 
diverse set of 496 cell lines from the Cancer Cell Line Encyclopedia (CCLE)31. For each cell 
line, CCLE contains gene expression, copy number variations, mutations in a preselected set of 
genes, and growth inhibition curves for 24 anticancer drugs. These drugs included both targeted 
agents such as Lapatinib, which inhibits two epithelial growth factor receptors (EGFR and 
ERBB2)32–34, and cytotoxic agents such as Irinotecan, a DNA Topoisomerase I inhibitor35. 
Although CCLE data has been extensively used to understand how drug response depends on 
specific alterations in cancer genes and changes in gene expression, the role of cumulative 
genetic load has not been explored previously.  
 
Our main conclusion is that genetic load indeed makes cancer less fit, i.e. passenger mutations 
reduce fitness components needed to survive treatment with anticancer drugs. The efficacy of 9 
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out of 24 drugs in CCLE increased significantly with genetic load. For certain drugs and tissue 
types, the association between the drug efficacy and genetic load was especially strong, 
explaining up to 83% of the variance. Overall, the role of genetic load depended on both the drug 
and the tissue type with 10 tissues being particularly vulnerable to genetic load. The type of 
genetic load also mattered. In particular, copy number changes and point mutations were 
uncorrelated and provided independent information about the effect of genetic load on a cell line.  
 
Genetic load also resulted in a distinct signature in gene expression changes, which included up-
regulation of cell-cycle checkpoints, DNA damage, apoptosis, and other pathways. We found 
that over or under expression of certain growth factors, such as ERBB2 and ERBB333, PDGFRA, 
PDGFRB37,38 and FGFR137,39 were strongly associated with an elevated number of point 
mutations. This observation further supports the findings of McFarland et al. 12, who 
experimentally demonstrated that the activation of growth factors contributes to mutagenesis. 
Collectively, our results confirm the important contribution of passenger alterations to tumor 
fitness and highlight the potential for using genetic load as a biomarker of drug response or even 
a therapeutic target. 
 
 
Results 
Our main goal was to test whether drug sensitivity increases with genetic load. To do so, we 
needed to quantify genetic load and drug sensitivity, and then perform a statistical test of positive 
correlation. Figure 1 illustrates this approach and graphically summarizes our methods. 
The drug sensitivity was quantified by the activity area, i.e. the area over the graph of relative 
growth inhibition vs. drug concentration. Previous studies based on CCLE data found that this 
metric was one of the most informative31,40–42, so we adopted it for our analysis. Two sources of 
information were available to quantify the genetic load: copy number changes and point 
mutations. We decided to quantify them separately and then investigated possible ways to 
combine these measures. 
 
Defining genetic load 
The copy number changes were quantified by the mean length of amplifications and deletions 
weighted by the magnitude of the log2 change in ploidy relative to the reference genome. This 
measure of alteration volume included several aspects that are likely to influence fitness and was 
robust to detection errors in very short segments. For point mutations, we considered several 
definitions based on, for example, only synonymous, only non-sense, only missense, or all 
polymorphisms. The results were similar, and, here, we used the total number of variants as the 
simplest measure. Note that we excluded all known driver genes from the analysis not to bias our 
estimate of the number of passenger mutations by the inclusion of possible drivers (see Methods 
section for further details).   
 
Since copy number changes and point mutations both contribute to cancer fitness, a combined 
measure of genetic load could have a greater predictive power. However, it is not clear a priori 
how to combine these measures at least for two reasons. First, the average fitness cost of copy 
number changes and point mutations could be different. Second, copy number changes and point 
mutations could be correlated. For example, positive correlations could appear because both 
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types of load increase with the total number of cell divisions since cancer initiation. Negative 
correlations could appear due to selection for an optimal net rate at which alterations are 
generated11. In such a case, a cancer with a high rate of point mutations would have fewer copy 
number changes. 
 
To address possible correlations, we computed the correlation coefficient between copy number 
changes and point mutation loads. The results are summarized in Figure 2, which shows no 
significant correlations either between raw metrics of genetic load, or between the metrics that 
were z-score normalized within each cancer type. In addition, we tested each tissue type 
independently and found no significant correlations between mutation and copy number loads 
(p>0.5). Given this independence between the metrics, we defined a combined genetic load as a 
linear combination of the copy number changes and point mutations. The weights in the linear 
combination were chosen to maximize its predictive ability of the drug response (see Methods). 
This definition also addressed the other difficulty raised above that the fitness costs of the two 
types of load could be different. In the following, we report the results for all three measures of 
genetic load: based on copy number changes only, based on point mutations only, and based on 
both.  
 
Testing for associations between genetic load and drug sensitivity 
Although testing for an association between genetic load and drug sensitivity seems 
straightforward, there are several caveats to consider due to cancer and drug heterogeneity. 
Indeed, cancer types have different amounts of copy number changes and point mutations on 
average and are likely to exhibit different sensitivities to the genetic load based on their 
phenotypic differences, for example, in protein production and metabolic rates. Drugs are also 
heterogeneous in their mechanism of action, and the effect of genetic load could vary greatly 
between the drugs. This combined variability due to drug and cancer type heterogeneity can 
easily obscure even a very strong association. Since many other factors such as specific 
mutations or expression patterns determine sensitivity to a given drug, the association between 
genetic load and drug response should not be particularly strong and care must be taken to 
control for heterogeneities in the data. Indeed, when we tested for an association between genetic 
load and drug response across all drugs and all cancer types we found no significant relationship 
for point mutation load (ρ=0.01, p=0.17 Spearman; r=0.003, p=0.4 Pearson) and only a weak 
relationship for copy number changes (ρ=0.03, p=0.002 Spearman; r=0.02, p=0.02 Pearson), as 
shown in Supplementary Figure 1. 
 
To address the concerns raised above, we report three types of association tests: (i) pan-cancer, 
with all tissue types included for each drug; (ii) pan-drug, with the response effectively averaged 
over the drugs for each tissue type; and (iii) one for all tissue-drug combinations tested 
separately. The benefit of the first two approaches is that they use larger subsets of the data and 
reduce the number of independent tests. The benefit of the last approach is that it avoids artifacts 
due to cancer and drug heterogeneity and can detect effects present only for specific tissue-drug 
combinations.  
 
Pan-cancer analysis 
For each drug, we tested for a positive correlation between genetic load and drug sensitivity 
across all cell lines in the data set. A sample plot from this pan-cancer analysis is shown in 
Figure 1B and the results are summarized in Table 1. At 10% false discovery rate for Spearman 
5 
 
correlation coefficient, we found that 9 out of 24 compounds show significant association 
between drug response and copy number load. In contrast, none of the associations reached 
significance for the point mutation load. For the combined load, we detected 7 significant 
associations that were identical to those for the copy number load. Table 2 shows all drugs with 
load-dependent activity along with their gene targets and mechanism of action. 
 
Pan-drug analysis 
The pan-cancer analysis demonstrated that genetic load plays a significant role in the efficacy of 
at least a third of drugs. Next, we examined how this association is affected by tissue 
heterogeneity. To this end, we compared the strength of associations between genetic load and 
drug response among different tissue types. To increase our statistical power, we included the 
data from all drugs, which affectively averages over the effects of different drugs. Figure 1B 
shows an example plot for this analysis and the results are summarized in Table 3. 
 
Out of 20 tissue types in the data set, we found that 10 different tissues were associated with 
either the point mutation load (7 tissues) or the copy number load (4 tissues). Almost the same 
list of tissues were also associated with the combined load. Thus, half of the analyzed tissue 
types are significantly affected by the genetic load. Moreover, the correlation coefficients and 
statistical significance increased substantially compared to the pan-cancer analysis reaching 
Spearman ρ as high as 0.43 and the FDR-corrected p-value as low as 10-8 (the associations based 
on the Pearson correlation coefficient were even stronger for some tissue types).  
 
The observed increase in the strength of the association reflects the important contribution of 
tissue heterogeneity, which is also evident by the variability of the inferred correlation 
coefficients across different tissues. This heterogeneity could reflect some important 
physiological differences between cancer types that require further study. For example, if fitness 
costs are due to protein misfolding the differences in chaperone expression and protein 
production rates could be important. At the very least, our analysis shows that genetic load could 
be an important biomarker for drug response especially in cancers of bone, thyroid, and liver. 
 
Analysis of specific tissue-drug combinations 
Finally, we analyzed specific tissue-drug combinations to further control for heterogeneity and 
see the full predictive power of genetic load. We analyzed 9 compounds and 10 tissue types that 
passed the FDR corrected p-value in the pan-cancer and pan-drug analyses for the mutation and 
copy number loads. The results are summarized in Table 4 for copy number, point mutation, and 
combined loads respectively. In total, 17 associations had FDR-adjusted level below 0.1 for 
Spearman correlation. The true number of associations could be much higher because the small 
size of the data set and the large number of tests might have prevented many tissue-drug 
combinations from reaching statistical significance. In the Supplemental Material, we provide 
evidence the pan-drug and pan-tissue results remain largely the same when the data on a 
significant tissue-drug combinations are excluded from the analysis (Supplementary Table 2). 
Therefore, the selection of drugs and tissues from Tables 2 and 3 in the above analysis does not 
affect the statistical significance. 
 
The correlation coefficients increased even further compared to the pan-drug analysis, explaining 
up to 83% of the variance that demonstrates an unexpectedly large effect of genetic load on drug 
sensitivity. In addition, the high correlation coefficients for tissue-drug pairs compared to pan-
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cancer and pan-drug analysis suggests that the fitness effects of genetic load are highly specific 
to both cancer type and therapeutic compound. We believe that one can obtain further insights 
into the biology of genetic load by trying to understand the pattern of specificity identified by our 
analysis. From a more clinical perspective, our results demonstrate that the tissue of origin and 
genetic load could be highly predictive of drug efficacy; it is therefore interesting to test whether 
genetic load could guide the choice of therapy for a given patient. 
 
The impact of the genetic load on gene expression 
The results presented above unequivocally support our hypothesis that passenger alterations 
reduce the fitness of cancer cells. A mechanistic understanding of this effect is however lacking. 
In particular, none of the drugs in CCLE was designed to increase the fitness cost of genetic 
load. In this section, we make a first step towards understanding the biology of passenger 
alterations by identifying changes in gene expression that are associated with genetic load.  
We selected 50 pathways for further analysis with genes involved in apoptosis, DNA damage, 
cell growth, cell cycle, and other processes related to cancer initiation and progression (see 
Methods section for further details). Then, for each selected pathway, we tested the correlation 
between the genetic loads and the pathway enrichment scores computed using Gene Set 
Variation Analysis (GSVA) for each sample43. Some of the key findings are discussed below and 
the complete list of significant associations is provided in Supplementary Tables 3 and 4 for 
point mutation and copy number loads, respectively. 
 
Overall, we found more pathways associated with mutation load compared to copy number load 
(26 vs. 7 pathways), that satisfied the FDR corrected p-value threshold of 0.1 for Spearman 
correlation coefficient. While this difference could truly reflect a greater and more varied 
response to the accumulation of point mutations, it is also possible that pathways associated with 
the response to copy number load are less well understood and annotated.  
 
The top positively associated pathways with the mutation load were apoptotic cleavage of cell 
adhesion proteins, activation of ATR in response to replication stress44, cell cycle checkpoints, 
G1S and G2M DNA damage checkpoints. The top negatively correlated ones were JNK, P38, 
MAPK45,46, GPCR47, and IGF48 signaling pathways. In addition, the copy number load was also 
positively associated with DNA damage processes, such as double strand break repair, G1S 
DNA damage checkpoints, DNA repair, ATM and E2F pathways, Therefore, an increased genetic 
load may indicate increased apoptosis and DNA damage, and decreased proliferation processes. 
Finally, we investigated the relationship between the expression of epithelial growth factors and 
genetic load. We singled out epithelial growth factors for three reasons. First, they play a major 
role in cancer and therefore are common targets for anticancer drugs. Second, the mechanism of 
action for 7 out of 9 drugs that showed significant association with genetic load involves growth 
factor pathways (all compounds in Table 2 except for Irinotecan and Topotecan). And third, 
experimental studies by McFarland et al.12 showed that activation of growth factor receptors, 
such as HER2/ERBB2, significantly increases the amount of accumulating copy number changes 
during mutagenesis.  
 
First, we selected 106 epithelial growth factor receptors and other related genes from UniProt 
database (http://www.uniprot.org) that overlapped with the CCLE data. We computed the 
correlation between the expression values of these growth receptors with the two genetic loads. 
Supporting McFarland’s observations, we found significant positive associations between the 
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epidermal growth factor receptors ERBB2 and ERBB3 and the point mutation load (FDR<0.1). 
In total, we found that the expression of 6 growth factor receptors and related genes was 
significantly positively associated with the point mutation load. In addition, the expression of 12 
such genes was significantly negatively associated with the point mutation load; see 
Supplementary Table 5. Interestingly, BRCA1 tumor suppressor, known to be involved in EGFR 
regulation49, was significantly positively associated with both the point mutation and the copy 
number loads. Except for a weak association with BRCA1 (ρ=0.13, FDR=0.07), the copy 
number load is not significantly associated with the expression of growth factor receptors. 
Although the overall picture of associations is complex, it clearly indicates that epithelial growth 
factor may play a role in mutation accumulation in addition to simply promoting cell growth.  
 
 
Discussion 
Cancer tumor is an instance of somatic evolution that favors uncontrolled proliferation over the 
wellbeing of the host. To understand and control cancer, we need to understand how evolution 
enables and constrains tumor progression. Evolution is rarely as simple as “the survival of the 
fittest”, and many evolutionary parameters such as mutation rates can both promote and inhibit 
adaptation10,11,24,50–52. At low mutation rates, extra mutations accelerate evolution by providing 
beneficial mutations and genetic diversity, which can become useful when tumor environment 
changes. In contrast, extra mutations could be a serious burden at high mutation rates because 
natural selection may fail to eliminate deleterious mutations before new ones appear. As a result, 
damaging mutations accumulate, reduce fitness, and interfere with the acquisition of beneficial 
mutations10,11,24,50. Where is cancer on this continuum from useful to harmful mutations? 
 
It has been well-established that high mutation rates facilitate tumor initiation and lead to a large 
number of passenger alterations in cancer genomes8. Here, we asked whether this accumulated 
genetic load significantly affects cancer fitness. Using the data from CCLE, we found that both 
point mutations and copy number changes make cancer more vulnerable to several drugs. The 
magnitude of this effect is highly heterogeneous and depends strongly both on the type of cancer 
and the drug. For some drug-tissue combinations, genetic load explains up to 83% of the 
variance in the drug response among the cell lines. The statistical dependence becomes weaker 
as more cancer and drug types are combined together, but never loses significance indicating that 
the fitness cost of genetic load is a very general phenomenon.  
 
There are several limitations of our study that might influence, but are unlikely to alter our 
results. The data in CCLE comes not from fresh tumor samples but from cancer cell lines that 
spend various amount of time growing under laboratory conditions. In addition, the fitness 
assays were carried out in vitro and do not take into account pharmacodynamics and the 
collateral damage to normal cells. However, the very large number of different cell lines in 
CCLE was chosen specifically to overcome these issues. Further, recent work demonstrated that 
a useful biomarker of clinical drug response can be developed from cell line data53,54. The 
performance of this cell-line-based biomarker often exceeds that of traditional biomarkers based 
on data derived from fresh tumor samples. Recent work also shows that previously reported 
inconsistencies among different cell line studies40 can be largely resolved by using more 
appropriate analysis methods, which we adopted in the this study42. 
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Another limitation is that point mutation data is available only for a preselected set of genes and 
no data on epigenetic mutations are available. While including epigenetic and whole genome 
sequencing data may improve the analysis, we found that including all profiled mutations or 
focusing just on synonymous mutations lead to similar conclusions presumably because the 
genes chosen for sequencing are representative of the genome overall. Moreover, the data on 
copy number changes was not affected by this bias and showed strong correlations with drug 
response as well.   
 
Beyond demonstrating that some passenger alterations are damaging to the tumor, our analysis 
uncovered important associations that might shed light on tumor biology. Specifically, we found 
that certain tissue-drug combinations are much more sensitive to genetic load than one would 
expect from the average effect of genetic load on that drug or tissue. Thus, isolating processes 
unique to these combinations may reveal how genetic load affects fitness. Our results also 
suggest that epithelial growth factor receptors, such as ERBB2, ERBB3, FGFR1, FGFR4 and 
others, may influence the rate of mutation accumulation, a finding that echoes recent 
experimental observations in mice12. In addition to growth factors, genetic load is strongly 
associated with several cancer pathways reflecting their involvement in either mutagenesis or 
response to a high genetic load. Some of these pathways are involved in DNA damage and cell 
cycle response, and their action could be quite similar to the commonly studied stress response to 
DNA damage due to a short pulse of radiation or a mutagen. However, other identified pathways 
could instead represent the long-term response to the costs of a genome full of many slightly 
damaging mutations.  
 
More important, the changes in gene expression associated with genetic load could provide the 
starting point to the design of therapies based on passenger rather than driver alterations. 
Simulation studies showed that such therapies are more effective than current approaches in part 
because normal cells have minimal genetic load10,11. Given the large fitness effects that we 
observe for drugs not designed to attack passengers, it is quite possible that therapies based on 
genetic load could be quite potent.  
 
In summary, we found how to quantify genetic load based on copy number and point mutation 
data. We then identified 9 drugs and 10 tissue types that are significantly affected by passenger 
alterations. Thus, the clinical decisions for these drugs and cancers could be improved by a 
biomarker based on genetic load. Overall, our findings confirm that passenger mutations reduce 
cancer fitness and identify important physiological changes associated with genetic load. Further 
studies on the biology of genetic load and its therapeutic potential could benefit not only cancer 
research, but also diseases related to aging such as Alzheimer’s disease55, where cells are known 
harbor many potentially deleterious mutations.  
 
 
Methods 
CCLE Data 
In this paper, we used publicly available data from the Cancer Cell Line Encyclopedia (CCLE)31. 
CCLE consortium profiled hundreds of cell lines from different cancer types. Representation of 
cell lines for each cancer type was mainly based on the cancer mortality in the United States31. 
For example, for cancer types with more than 7,000 deaths/year, a maximum of 60 cell lines 
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were profiled; for the other types, 15 was the desired minimum number of cell lines. We 
included data profiled from 20 different tissue types, excluding those with too few cell lines to 
provide sufficient statistical power. Specifically, we excluded all tissue types with fewer than 8 
cell lines, such as salivary gland, biliary tract and prostate. The number of cell lines available for 
each tissue and each data type are shown in Supplementary Table 1. Most cell lines had both 
copy number point mutation profiles; see Supplementary Table 1. 
 
We used copy number estimates profiled and normalized by CCLE31. This data was generated on 
genome-wide human Affymetrix SNP Array 6.0, normalized to log2-ratios, segmented using 
CBS (Circular Binary Segmentation)56, and  median  centered to  zero  in  each  sample 31. 
Somatic variants were measured via hybrid capture exome sequencing. A number of 1651 
protein-coding genes were sequenced based on their known or potential involvement in tumor 
biology31. In the paper, we focused on common polymorphisms, so the variants with allelic 
fraction <10% were filtered out. 
 
We also downloaded gene expression data generated on Affymetrix Human Genome U133 Plus 
2.0 arrays and normalized using RMA (Robust Multichip Average)31,57. CCLE gene expression 
data was profiled genome-wide for 675 cell lines. 
 
Finally, we considered the publicly available drug response data for 24 anticancer drugs profiled 
across 496 cell lines and 20 tissue types31 (Supplementary Table 1). CCLE generated eight-point 
dose–response curves for each of the 24 compounds using an automated compound-screening 
platform31. We used the drug activity area as a measure of drug response because previous 
studies found it most informative31,40–42. 
 
Estimating genetic load from copy number and point variants 
The copy number changes were quantified by the normalized and segmented log2-ratios relative 
to haploid genome. These log2-ratios are positive for copy number gain and negative for copy 
number loss. For each cell line, we computed the mean volume of the copy number alterations, 
where the volume is the absolute value of the copy number change multiplied by the region’s 
length. Thus, amplifications and deletions contributed equally to the copy number load. 
 
The somatic variants were profiled for 1651 protein-coding genes known to be involved in tumor 
biology. This choice of genes is not ideal for our purpose to estimate the genetic load caused by 
the accumulation of passenger mutations because some of these genes could be hot spots for 
driver mutations. To avoid possible biases, we filtered out the 125 known oncogenes and tumor 
suppressors58.  Then, from a total number of 66613 variants, we estimated the mutation genetic 
load of each cell line as the total number of variants in that cell line.  
 
Next, we used correlation analysis to identify the effect of genetic load on drug sensitivity. 
Because of the major differences between cancer types, the copy number load, the mutation load, 
and the activity area, were z-score normalized for each cancer type separately by subtracting the 
mean and dividing by the standard deviation. Then, we computed the correlation coefficient 
between the genetic load scores for a relevant subset of cell lines and the activity area of the 
compound data. Both Spearman and Pearson correlation coefficients are reported. However, we 
believe that the nonparametric Spearman coefficient is more appropriate for our analysis because 
it is more robust against outliers59, and the relationship between genetic load and drug activity 
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could be nonlinear. The statistical hypothesis tested was that the Spearman correlation 
coefficient is greater than zero, and we corrected the p-values using the False Discovery Rate 
(FDR)60.  
 
To combine the two genetic loads, we used a generalized linear model with lasso regularization 
(cv.glmnet function in R programming language): the activity area was the response variable and 
the two genetic loads were the independent variables. Then, we computed the correlation 
between the predicted activity area and the real value. The correlation p-values were adjusted 
across all computed values (those for which the lasso regularization reached a solution and the 
coefficients corresponding to the explanatory variables were non-zero). This procedure could 
slightly inflate statistical significance because the same data was used to estimate the relative 
weights of the two loads and to test for association between the combined load and drug 
response. However, this was a reasonable approach given the small number of cell line for 
specific tissues. Moreover, our procedure enabled an easy comparison to the correlation analyses 
based on a single type of genetic load. Note that the combined load largely recapitulated the 
results from the point mutation and copy number loads suggesting that overfitting was not a 
major issue in the analysis.  
 
Associations between genetic load and gene expression 
To identify cellular pathways most the affected by the genetic load, we tested for associations 
between the load and gene expression enrichment scores. First, a set of 50 pathways from 
MSigDb (C2, Canonical Pathways) were selected based on their relevance to DNA damage/repair, 
cell growth and cell cycle checkpoints. We were particularly interested in those gene sets that included 
the words “repair”, “damage”, “growth”, “apoptosis”, “checkpoints”, “angiogenesis”, “autophagy”, and 
the most known cell growth signaling pathways such as “MAPK”, “PI3K/AKT”, “P53 DNA damage 
response”, “ERBB network”, “NOTCH signaling”, “MTOR signaling” and “TGF-beta”. To reduce 
noise and redundant pathway information from MSigDB, we curated the pathways using 
pathway maps illustrated in Cell Signaling Technology Guide (Pathways and Protocols)61. Next, 
we computed the pathway enrichment scores in each sample using GSVA43 for the selected 
pathways. All cell lines with available gene expression and genetic data (620 for point mutations 
and 674 for copy number) were included in the analysis. For each selected pathway, we 
computed the correlation between the enrichment scores and the genetic loads (separately for the 
point mutation load and the copy number load). 
 
Furthermore, to address the McFarland’s observations that activated growth factor receptors 
promote mutagenesis12, we analyzed the relationship between the expression of epithelial growth 
factor receptors and other related genes, to the point mutation and copy number loads. We used 
UniProt (http://www.uniprot.org) database (by searching for “human epithelial growth factor 
receptor”) and overlapped the resulting list of genes with the CCLE data. We computed the 
correlations coefficients between gene expression of 106 growth factors and other related genes, 
with the two genetic loads.  
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Figures and Tables 
 
Figure 1. Testing the relationship between genetic load and drug sensitivity. (A) The first 
row illustrates the quantification of genetic load and drug sensitivity. From left to right: copy 
number load is measured as the mean absolute volume of amplifications and deletions, 
mutational load is defined as the total number of polymorphisms, and drug sensitivity is 
quantified by the area over the dose-response curve; see Methods for more details. (B) The 
second row illustrates three types of correlation analysis performed on the z-score normalized 
values: pan-cancer, pan-drug, and for specific tissue-drug combinations. Representative 
significant associations are shown. Note that the negative load reflects the normalization of 
genetic load accomplished by subtracting the mean load for the tissue type and then dividing by 
the standard deviation of the load in that tissue type. 
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Figure 2. Correlation between copy number and point mutation loads. Copy number and 
point mutation measures of genetic load are uncorrelated. We combined all cell lines in the data 
set for this analysis. The left panel shows raw measures of load, while the right panel shows 
measures that were z-score normalized within each tissue type (i.e. divide by the the standard 
deviation after subtracting the mean). 
 
 
Table 1. Significant associations for the pan-cancer analysis. 
Genetic load Drug Spearman Pearson No. cells 
ρ FDR r FDR 
 
 
 
Copy number 
load 
Erlotinib 0.13 0.04 0.11 0.04 486 
Lapatinib 0.12 0.06 0.11 0.04 487 
TKI258 0.11 0.06 0.13 0.04 487 
Sorafenib 0.09 0.06 0.12 0.04 486 
AEW541 0.1 0.06 0.09 0.11 486 
Irinotecan 0.12 0.06 0.09 0.21 304 
Nilotinib 0.1 0.06 0.07 0.24 403 
TAE684 0.09 0.06 0.04 0.44 487 
Topotecan 0.09 0.06 0.07 0.21 487 
 
 
 
Combined load 
Erlotinib 0.13 0.02 0.11 0.02 441 
Lapatinib 0.11 0.03 0.12 0.02 442 
TKI258 0.11 0.03 0.12 0.02 442 
AEW541 0.1 0.03 0.08 0.06 441 
Topotecan 0.1 0.03 0.07 0.09 442 
Nilotinib 0.1 0.03 0.06 0.12 363 
Sorafenib 0.08 0.05 0.11 0.02 441 
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Table 2. Significant drugs in pan-cancer analysis and their gene targets (the targets, 
predictors of sensitivity and mechanisms of action were included from the CCLE study31). 
Drug Gene targets Predictor of sensitivity Mechanism of action 
Erlotinib EGFR EGFR mutation EGFR  inhibitor 
Lapatinib ERBB2, EGFR ERBB2 expression EGFR and ERBB2 
inhibitor 
TKI258 EGFR, FGFR1, PDGFRbeta, 
VEGFR-1, KDR 
Unknown Multi-kinase inhibitor 
Sorafenib FLT3, C-KIT, PDGFRbeta, 
RET, Raf kinase B, Raf kinase 
C, VEGFR-1, KDR, FLT4 
Unknown Multi-kinase inhibitor 
AEW541 IGF1R IGF1R expression Kinase inhibitor 
Irinotecan Topoisomerase I Unknown DNA Topoisomerase I 
Inhibitor 
Nilotinib Abl/Bcr-Abl Unknown Abl Inhibitor 
TAE684 ALK Unknown ALK Inhibitor 
Topotecan Topoisomerase I Unknown DNA Topoisomerase I 
Inhibitor 
 
Table 3. Significant associations for the pan-drug analysis. 
Genetic 
load 
Tissue  
type 
Spearman Pearson No. cells 
ρ FDR r FDR 
 
 
 
Point 
mutation 
load 
BONE 0.34 10-6 0.33 10-6 260 
LIVER 0.26 10-5 0.27 10-5 338 
THYROID 0.43 10-5 0.44 10-5 120 
CENTRAL NERVOUS 
SYSTEM 
0.18 10-4 0.13 10-3 576 
STOMACH 0.15 0.01 0.31 10-7 349 
PANCREAS 0.09 0.05 0.07 0.16 599 
LUNG 0.04 0.08 0.04 0.09 1997 
 
Copy 
number 
load 
SKIN 0.16 10-5 0.15 10-5 936 
LIVER 0.14 0.01 0.13 0.02 434 
HAEMATOPOIETIC 
AND LYMPHOID 
TISSUE 
0.07 0.01 0.06 0.03 1677 
ENDOMETRIUM 0.15 0.01 0.08 0.14 458 
 
 
 
 
 
 
Combined 
load 
BONE 0.38 10-8 0.34 10-8 236 
LIVER 0.29 10-7 0.37 10-11 338 
THYROID 0.43 10-6 0.44 10-6 120 
CENTRAL NERVOUS 
SYSTEM 
0.18 10-5 0.13 10-3 576 
SKIN 0.13 10-4 0.13 10-4 841 
ENDOMETRIUM 0.15 10-3 0.08 0.05 458 
HAEMATOPOIETIC 
AND LYMPHOID 
TISSUE 
0.08 10-3 0.07 10-3 1535 
STOMACH 0.15 10-3 0.31 10-8 349 
PANCREAS 0.10 0.01 0.07 0.05 551 
LARGE INTESTINE 0.09 0.03 0.12 0.01 488 
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Table 4. Significant associations for tissue-drug combinations. 
Genetic load Tissue type Drug Spearman Pearson No. 
cells ρ FDR r FDR 
Point mutation load CENTRAL NERVOUS SYSTEM Sorafenib 0.69 0.01 0.56 0.18 25 
 
Copy number load 
ENDOMETRIUM Lapatinib 0.69 0.03 0.58 0.11 20 
LIVER Irinotecan 0.83 0.06 0.79 0.11 11 
STOMACH TAE684 0.64 0.06 0.59 0.11 19 
 
 
 
 
 
 
 
 
Combined load 
CENTRAL NERVOUS SYSTEM Sorafenib 0.69 10-3 0.56 0.02 25 
ENDOMETRIUM Lapatinib 0.69 10-3 0.58 0.02 20 
LIVER Lapatinib 0.6 0.04 0.68 0.02 15 
STOMACH TAE684 0.65 0.04 0.60 0.04 15 
ENDOMETRIUM Erlotinib 0.52 0.04 0.47 0.04 20 
BONE Sorafenib 0.75 0.04 0.59 0.06 10 
BONE Nilotinib 0.81 0.04 0.59 0.08 8 
LIVER Nilotinib 0.73 0.04 0.84 0.02 9 
SKIN Erlotinib 0.36 0.04 0.33 0.05 36 
BONE Erlotinib 0.7 0.04 0.54 0.08 10 
PANCREAS Irinotecan 0.52 0.05 0.53 0.04 16 
STOMACH TKI258 0.51 0.05 0.48 0.06 15 
SKIN Topotecan 0.33 0.05 0.37 0.04 36 
LIVER Irinotecan 0.71 0.08 0.81 0.04 7 
BONE AEW541 0.58 0.08 0.67 0.04 10 
HAEMATOPOIETIC AND 
LYMPHOID TISSUE TKI258 0.21 0.08 0.29 0.04 65 
HAEMATOPOIETIC AND 
LYMPHOID TISSUE Erlotinib 0.2 0.08 0.19 0.08 65 
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Supplementary Figures and Tables 
 
Supplementary Figure 1. Pan-data analysis for the mutation load (left) and the copy 
number load (right). 
 
 
  
Supplementary Table 1. Twenty CCLE tissue types analyzed in this work. 
 
TISSUE TYPE 
Number of cell lines with 
profiled copy number data 
(1017) 
Number of cell lines 
with profiled point 
mutation data (888) 
HAEMATOPOIETIC AND LYMPHOID 
TISSUE 
188 165 
LUNG 185 172 
CENTRAL NERVOUS SYSTEM 68 44 
SKIN 61 53 
BREAST 59 51 
LARGE INTESTINE 59 56 
OVARY 53 47 
PANCREAS 44 37 
STOMACH 39 34 
KIDNEY 36 22 
UPPER AERODIGESTIVE TRACT 31 31 
ENDOMETRIUM 28 27 
BONE 28 22 
LIVER 27 24 
OESOPHAGUS 27 25 
URINARY TRACT 24 24 
SOFT TISSUE 21 18 
AUTONOMIC GANGLIA 17 15 
THYROID 12 11 
PLEURA 10 10 
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Supplementary Table 2. Significant associations for tissue-drug combinations with 
exclusion of tested drug-tissue combination from pan cancer and pan drug analyses. In the 
analysis of drug-tissue combinations, we preselected drugs and tissues based on the association 
with genetic load. Thus, some of the data was used twice: once in the selection step and once in 
the correlation test. Overall, the number of cell lines used twice was typically less than 10%, and, 
in many cases, pre-selection was based on a different measure of genetic load than the 
correlation test, i.e. on a different data. Nevertheless, we modified the analysis to ensure that 
statistical significance is not affected. We screened all tissue-drug combinations, not just those 
from Tables 2 and 3. For each combination, we first tested whether the tissue and the drug are 
associated with genetic load when the data from the combination is excluded. The combination 
was considered further only if pan-drug and pan-cancer analyses (with exclusion) showed 
positive association with the genetic load (Spearman FDR less than 0.1). For each combination 
passing this test, we computed the correlation between the Activity Area and the genetic load and 
performed FDR calculation based on the total number of combinations passing the test for each 
load. 
 
Genetic load Tissue type Drug Spearman Pearson No. 
cells ρ FDR r FDR 
Point mutation load LUNG Lapatinib 0.39 0.08 0.55 0.02 15 
 
Copy number load 
ENDOMETRIUM Lapatinib 0.69 0.01 0.58 0.04 20 
LIVER Irinotecan 0.83 0.01 0.79 0.03 11 
ENDOMETRIUM Erlotinib 0.64 0.06 0.47 0.12 20 
 
 
 
 
Combined load 
ENDOMETRIUM Lapatinib 0.69 10-3 0.58 0.01 20 
LIVER Lapatinib 0.69 0.01 0.68 0.01 15 
ENDOMETRIUM Erlotinib 0.6 0.01 0.47 0.03 20 
LIVER Nilotinib 0.65 0.02 0.84 0.01 9 
STOMACH TKI258 0.52 0.03 0.48 0.05 15 
LIVER Topotecan 0.75 0.08 0.57 0.03 15 
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Supplementary Table 3.  Associations between cancer pathways and point mutation load. 
PATHWAY Spearman Pearson 
ρ FDR r FDR 
REACTOME_APOPTOTIC_CLEAVAGE_OF_CEL
L_ADHESION_PROTEINS 
0.25 10-7 0.27 10-9 
ST_JNK_MAPK_PATHWAY -0.24 10-7 -0.13 0.01 
REACTOME_GPCR_DOWNSTREAM_SIGNALIN
G 
-0.23 10-6 -0.26 10-8 
PID_P38_ALPHA_BETA_PATHWAY -0.21 10-5 -0.15 10-3 
KEGG_MAPK_SIGNALING_PATHWAY -0.21 10-5 -0.12 0.01 
REACTOME_ACTIVATION_OF_ATR_IN_RESPO
NSE_TO_REPLICATION_STRESS 
0.19 10-4 0.07 0.18 
REACTOME_CELL_CYCLE_CHECKPOINTS 0.19 10-4 0.11 0.02 
REACTOME_SIGNALING_BY_GPCR -0.19 10-4 -0.26 10-9 
REACTOME_REGULATION_OF_INSULIN_LIKE
_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSU
LIN_LIKE_GROWTH_FACTOR_BINDING_PROT
EINS_IGFBPS 
-0.19 10-4 -0.13 0.01 
REACTOME_G2_M_CHECKPOINTS 0.18 10-4 0.07 0.18 
PID_LYMPH_ANGIOGENESIS_PATHWAY -0.15 10-3 -0.17 10-4 
REACTOME_G2_M_DNA_DAMAGE_CHECKPOI
NT 
0.13 0.01 0.05 0.38 
REACTOME_P53_DEPENDENT_G1_DNA_DAM
AGE_RESPONSE 
0.12 0.01 0.12 0.01 
REACTOME_P53_INDEPENDENT_G1_S_DNA_D
AMAGE_CHECKPOINT 
0.12 0.01 0.05 0.34 
PID_E2F_PATHWAY 0.12 0.01 0.06 0.23 
REACTOME_GROWTH_HORMONE_RECEPTOR
_SIGNALING  
-0.11 0.02 -0.07 0.21 
KEGG_MTOR_SIGNALING_PATHWAY -0.11 0.02 -0.14 10-3 
REACTOME_DNA_REPAIR 0.11 0.02 0.03 0.61 
REACTOME_APOPTOTIC_EXECUTION_PHASE 0.11 0.02 0.17 10-4 
REACTOME_EXTRINSIC_PATHWAY_FOR_APO
PTOSIS 
-0.10 0.03 -0.02 0.71 
PID_ERBB_NETWORK_PATHWAY 0.10 0.03 0.12 0.01 
PID_ATM_PATHWAY 0.10 0.04 0.02 0.71 
REACTOME_APOPTOTIC_CLEAVAGE_OF_CEL
LULAR_PROTEINS 
0.09 0.04 0.12 0.01 
KEGG_NOTCH_SIGNALING_PATHWAY 0.09 0.05 0.15 10-3 
REACTOME_NRAGE_SIGNALS_DEATH_THRO
UGH_JNK 
-0.09 0.05 0.14 10-3 
REACTOME_SIGNALING_BY_HIPPO 0.08 0.07 0.05 0.33 
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Supplementary Table 4.  Associations between cancer pathways and copy number load. 
PATHWAY Spearman Pearson 
ρ FDR r FDR 
PID_P38_ALPHA_BETA_DOWNSTREAM_PATHWA
Y 
0.12 0.03 0.11 0.06 
REACTOME_HOMOLOGOUS_RECOMBINATION_R
EPAIR_OF_REPLICATION_INDEPENDENT_DOUBL
E_STRAND_BREAKS 
0.12 0.03 0.12 0.06 
REACTOME_DOUBLE_STRAND_BREAK_REPAIR 0.12 0.03 0.12 0.06 
PID_E2F_PATHWAY 0.12 0.03 0.07 0.39 
REACTOME_P53_INDEPENDENT_G1_S_DNA_DA
MAGE_CHECKPOINT 
0.11 0.04 0.09 0.14 
PID_ATM_PATHWAY 0.11 0.04 0.10 0.07 
REACTOME_DNA_REPAIR 0.10 0.09 0.09 0.14 
 
Supplementary Table 5. Associations between epithelial growth factor receptors and other 
related genes and point mutation load. 
GENE 
 
Spearman Pearson 
ρ FDR r FDR 
TGFB1 -0.21 10-5 -0.14 0.01 
PML -0.21 10-5 -0.20 10-4 
ERBB3 0.18 10-4 0.16 10-3 
SGK3 0.19 10-4 0.08 0.16 
SMAD3 -0.17 10-4 -0.08 0.17 
TGFB2 -0.17 10-4 -0.11 0.03 
MMP2 -0.17 10-4 -0.12 0.02 
MYLK -0.16 10-3 -0.13 0.01 
PAK2 -0.16 10-3 -0.12 0.03 
FGFR4 0.15 10-3 0.17 10-3 
JAG2 0.14 10-3 0.14 0.01 
BRCA1 0.13 0.01 0.05 0.45 
FGFR1 -0.14 0.01 -0.04 0.60 
VEGFC -0.13 0.01 -0.15 10-3 
ELF4 -0.13 0.01 -0.10 0.07 
PTEN -0.11 0.04 -0.04 0.54 
ERBB2 0.10 0.06 0.14 0.01 
INHBA -0.10 0.07 -0.09 0.12 
 
 
 
